



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heikki HYOTY, et al
Application No.: 10/009,016 Group No.: 1645
Filed: March 12, 2002 Examiner: Mary Mosher
For: PREVENTION OF TYPE 1 DIABETES AND OTHER NON-POLIO
ENTEROVIRUS DISEASES

Attorney Docket No.: U 013757-2

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE

Further to Applicants' Amendment dated 15 November 2004, and in
supplemental response to the Official Action of 15 June 2004, Applicants submit

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

- ☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office to (708) 872-9306

Date: January 5, 2005

Signature

CLIFFORD J. MASS

(type or print name of person certifying)


***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

herewith copies of publications which substantiate the remarks in Applicants' aforementioned Amendment regarding the recent studies which have been carried out that demonstrate the connection between enterovirus infections and type 1 diabetes (see Amendment dated 15 November 2004 at page 13, first paragraph). The studies include studies published by the group of the inventors and studies demonstrating the presence of enterovirus in the pancreatic islets in diabetic or prediabetic subjects.

An Information Disclosure Statement including citation of the aforementioned publications is also submitted herewith.

An early and favorable reconsideration of the application in view of the present submission is again respectfully requested.

Respectfully submitted,



CLIFFORD J. MASS
LADAS & PARRY LLP
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.30,086(212)708-1890